OBI Pharma
Market Cap
NT$21.4b
Last Updated
2021/01/21 17:31 UTC
Data Sources
Company Financials
Executive Summary
OBI Pharma, Inc., a bio-pharma company, develops and licenses therapeutic agents for unmet medical needs against cancer in Taiwan. More Details
Risk Analysis
Snowflake Analysis
Excellent balance sheet with weak fundamentals.
Share Price & News
How has OBI Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4174 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 4174's weekly volatility (6%) has been stable over the past year.
Market Performance
7 Day Return
-5.0%
4174
-2.3%
TW Biotechs
-0.2%
TW Market
1 Year Return
-13.7%
4174
21.7%
TW Biotechs
28.6%
TW Market
Return vs Industry: 4174 underperformed the TW Biotechs industry which returned 21.7% over the past year.
Return vs Market: 4174 underperformed the TW Market which returned 28.6% over the past year.
Shareholder returns
| 4174 | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.0% | -2.3% | -0.2% |
| 30 Day | -20.1% | -7.8% | 8.8% |
| 90 Day | 0% | -2.8% | 20.6% |
| 1 Year | -13.7%-13.7% | 22.2%21.7% | 33.1%28.6% |
| 3 Year | -37.3%-37.3% | -17.7%-19.2% | 55.3%37.8% |
| 5 Year | -81.1%-81.1% | -48.1%-48.6% | 135.7%94.2% |
Long-Term Price Volatility Vs. Market
How volatile is OBI Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Here's Why OBI Pharma (GTSM:4174) Can Manage Its Debt Despite Losing Money1 month ago | Simply Wall St
If You Had Bought OBI Pharma's (GTSM:4174) Shares Five Years Ago You Would Be Down 82%3 months ago | Simply Wall St
Is OBI Pharma (GTSM:4174) Using Too Much Debt?Valuation
Is OBI Pharma undervalued compared to its fair value and its price relative to the market?
5.15x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 4174's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 4174's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 4174 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.
PE vs Market: 4174 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4174's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4174 is overvalued based on its PB Ratio (5.1x) compared to the TW Biotechs industry average (4.8x).
Next Steps
Future Growth
How is OBI Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
86.2%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OBI Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine OBI Pharma's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has OBI Pharma performed over the past 5 years?
-9.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4174 is currently unprofitable.
Growing Profit Margin: 4174 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 4174 is unprofitable, and losses have increased over the past 5 years at a rate of 9.3% per year.
Accelerating Growth: Unable to compare 4174's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4174 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).
Return on Equity
High ROE: 4174 has a negative Return on Equity (-33.99%), as it is currently unprofitable.
Next Steps
Financial Health
How is OBI Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: 4174's short term assets (NT$4.0B) exceed its short term liabilities (NT$176.7M).
Long Term Liabilities: 4174's short term assets (NT$4.0B) exceed its long term liabilities (NT$169.8M).
Debt to Equity History and Analysis
Debt Level: 4174's debt to equity ratio (1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 4174's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4174 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 4174 has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 14.8% each year.
Next Steps
Dividend
What is OBI Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 4174's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 4174's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4174's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4174's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4174's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.4yrs
Average management tenure
CEO
Michael N. Chang (70 yo)
1.42yrs
Tenure
NT$2,563,000
Compensation
Dr. Michael N. Chang, Ph.D., serves as Partner at Delos Advisors Limited. He served as Consultant of Optimer Pharmaceuticals, Inc. since May 2010. Dr. Chang co-founded Optimer Pharmaceuticals, Inc. in Nove...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.42yrs | NT$2.56m | no data | |
| CFO & Director | 4.58yrs | NT$55.00k | no data | |
| Chief Scientific Officer | 1.33yrs | no data | no data | |
| Director of Public Relations & Government Affairs Division | 4.83yrs | no data | no data | |
| Chief Medical Advisor | 0.83yr | no data | no data | |
| Chief Commercial Officer of USA | 8yrs | no data | no data | |
| Chief Medical Officer | 1.25yrs | no data | no data | |
| Chief Operating Officer of USA | 7.33yrs | no data | no data | |
| Chief Executive Officer of OBI Pharma (Shanghai) Limited | 1.17yrs | no data | no data |
1.4yrs
Average Tenure
62.5yo
Average Age
Experienced Management: 4174's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.42yrs | NT$2.56m | no data | |
| CFO & Director | 4.58yrs | NT$55.00k | no data | |
| Director | no data | no data | no data | |
| Director | 7.92yrs | NT$45.00k | no data | |
| Independent Director | 6.5yrs | NT$700.00k | no data | |
| Independent Director | 4.58yrs | NT$700.00k | no data |
4.6yrs
Average Tenure
65yo
Average Age
Experienced Board: 4174's board of directors are considered experienced (4.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
OBI Pharma, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: OBI Pharma, Inc.
- Ticker: 4174
- Exchange: GTSM
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$21.405b
- Shares outstanding: 188.59m
- Website: https://www.obipharma.com
Location
- OBI Pharma, Inc.
- No. 3, Park Street
- Room 1907, 19th Floor
- Taipei
- 115
- Taiwan
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 4174 | GTSM (Taipei Exchange) | Yes | Common Stock | TW | TWD | Dec 2012 |
Biography
OBI Pharma, Inc., a bio-pharma company, develops and licenses therapeutic agents for unmet medical needs against cancer in Taiwan. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity a...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/21 17:31 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.